GVS S.p.A GVS

Why GVS stock is in focus after fresh half year earnings GVS (BIT:GVS) is back on investors’ radar after reporting half year 2026 results on 6 August, with broadly steady sales and revenue but a sharp move in net income. See our latest analysis for GVS. The half year results appear to have reset expectations around GVS, with the stock posting a 1 day share price return of 9.52% and a 90 day share price return of 17.27%. However, the 5 year total shareholder return is down 66.14%, which shows...

GVS SpA (LTS:0GV5) delivers solid H1 2026 with margin expansion and strong pricing power, while management maintains prudent guidance amid geopolitical complexity.

MILAN, June 17, 2026--WISE S.p.A., a pioneering medical device company specializing in advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface (BCI), today announced the successful closing of an oversubscribed Series D financing round totaling €30 million. The round was joined by ENEA Tech and Biomedical, an Italian foundation dedicated to innovation and technology transfer in the biomedical sector, which enters WISE's investor base as a strategic partn

GVS SpA (STU:4YQ) reports a 2% revenue increase and improved EBITDA margins, while navigating challenges in the Energy Mobility and US Dialysis sectors.

GVS SpA (STU:4YQ) reports robust EBITDA margin improvements and strategic advancements despite facing currency and volume challenges in Q3 2025.